BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Eisai Inc. (ESALF.PK)’s Perampanel Didn’t Significantly Reduce Epileptic Seizures in Study


4/14/2011 10:51:42 AM

Bloomberg -- Eisai Co.’s experimental epilepsy drug didn’t cut seizure rates significantly more than a placebo in patients who didn’t improve on previous treatments, a researcher said at the American Academy of Neurology meeting. While the study failed to find a definitive benefit for its two main goals, a third analysis favored by U.S. regulators showed patients had 26 percent to 35 percent fewer seizures over 28 days on perampanel, compared with 21 percent in those on a placebo, said Jacqueline French, director of the clinical trials consortium at New York University’s epilepsy center.

Read at News Release
Read at WebMD
Read at Bloomberg

   
Epilepsy

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES